Magnus Mcleod

Halifax, NS, CA 
Halifax, NS, CA 

Overview

Magnus Mcleod practices practicing medicine in Halifax, Canada.

His clinical expertise encompasses Lipidosis with Triglycerid Storage Disease, Panhypopituitarism, Enlarged Liver, and Non-Alcoholic Fatty Liver Disease.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Halifax, NS, Canada
Other Locations
Health PEI
Charlottetown, PE, Canada
Prince Edward Island, PE, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

10 Total Publications

Long-term clinical outcomes in lysosomal acid lipase deficiency: Fibrosis regression with sebelipase alfa therapy.
Long-term clinical outcomes in lysosomal acid lipase deficiency: Fibrosis regression with sebelipase alfa therapy.
Journal: Canadian liver journal
Published: May 08, 2025

Frequently Asked Questions about Magnus Mcleod

Is Magnus Mcleod a top-rated expert for Lipidosis with Triglycerid Storage Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Magnus Mcleod is classified as an Experienced expert for Lipidosis with Triglycerid Storage Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Magnus Mcleod participate in research or clinical trials?

Yes. Magnus Mcleod has published 10 articles and abstracts on conditions like Lipidosis with Triglycerid Storage Disease. You can view a list of Magnus Mcleod's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mcleod's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile